www.covid-19-vaccine-tracker.com Open in urlscan Pro
104.21.85.16  Public Scan

Form analysis
0 forms found in the DOM

Text Content

WE AGGREGATE INFORMATION ABOUT VACCINES COVID-19

All companies, countries around the world do researches about covid-19 and make
attempts to develop new more efficient vaccines.

The COVID-19 candidate vaccine landscape and tracker database compiles detailed
information on COVID-19 vaccine candidates in development.

The landscape:

 * provides summary tables of COVID-19 vaccine candidates in both clinical and
   pre-clinical development;
 * provides analysis and visualization for several COVID-19 vaccine candidate
   categories;
 * tracks the progress of each vaccine from pre-clinical, Phase 1, Phase 2
   through to Phase 3 efficacy studies and including Phase 4 registered as
   interventional studies;
 * provides links to published reports on safety, immunogenicity and efficacy
   data of the vaccine candidates;
 * includes information on key attributes of each vaccine candidate and
 * allows users to search for COVID-19 vaccines through various criteria such as
   vaccine platform, schedule of vaccination, route of administration,
   developer, trial phase and clinical endpoints.

You can download file from world health organization here

Vaccines authorized for emergency use or approved for full use Vaccine,
developers/sponsors Country of origin Type (technology) Doses, interval Storage
temperature Pre-marketing study (participants) Postmarketing study
(participants) Authorization Oxford–AstraZeneca COVID-19 vaccine (Vaxzevria,
Covishield)
University of Oxford, AstraZeneca, CEPI United Kingdom, Sweden Adenovirus vector
(ChAdOx1) 2 doses
4–12 weeks 2–8 °C Phase III (30,000)
Interventional; randomized, placebo-controlled study for efficacy, safety, and
immunogenicity.
Overall efficacy of 76% after the first dose and 81% after a second dose taken
12 weeks or more after the first.
May 2020 – Aug 2021, Brazil (5,000), United Kingdom, India Phase IV (10,000)
Interventional, non-randomized
Feb 2021 – Dec 2024, Denmark Full (2)
Emergency (168) Pfizer–BioNTech COVID-19 vaccine (Comirnaty)
BioNTech, Pfizer Germany, United States RNA (modRNA in lipid nanoparticles) 2
doses
3–4 weeks −70±10 °C
(ULT) Phase III (43,448)
Randomized, placebo-controlled.
Positive results from an interim analysis were announced on 18 November 2020 and
published on 10 December 2020 reporting an overall efficacy of 95%.
Jul–Nov 2020, Germany, United States Phase IV (10,000)
Interventional, non-randomized
Feb 2021 – Dec 2024, Denmark Full (5)
Emergency (107) Sputnik V COVID-19 vaccine (Gam-COVID-Vac)
Gamaleya Research Institute of Epidemiology and Microbiology Russia Adenovirus
vector (recombinant Ad5 and Ad26) 2 doses
3 weeks ≤−18 °C
(freezer) Phase III (40,000)
Randomized double-blind, placebo-controlled to evaluate efficacy,
immunogenicity, and safety.
Interim analysis from the trial was published in The Lancet, indicating 91.6%
efficacy without unusual side effects.
Aug 2020 – May 2021, Russia, Belarus, India, Venezuela, UAE Full (2)
Emergency (70) BBIBP-CorV
Sinopharm: Beijing Institute of Biological Products China Inactivated SARS‑CoV‑2
(vero cells) 2 doses
3–4 weeks 2–8 °C Phase III (48,000)
Randomized, double-blind, parallel placebo-controlled, to evaluate safety and
protective efficacy.
Peer-reviewed results indicate 78.1% efficacy against symptomatic COVID-19.
Jul 2020 – Jul 2021, United Arab Emirates, Bahrain, Jordan, Argentina, Morocco,
Peru Full (4)
Emergency (67) Moderna COVID-19 vaccine (TAK-919)
Moderna, NIAID, BARDA, CEPI United States RNA (modRNA in lipid nanoparticles) 2
doses
4 weeks −20±5 °C
(freezer) Phase III (30,000)
Interventional; randomized, placebo-controlled study for efficacy, safety, and
immunogenicity.
Positive results from an interim analysis were announced on 15 November 2020 and
published on 30 December 2020 reporting an overall efficacy of 94%.
Jul 2020 – Oct 2022, United States Phase IV (10,000)
Interventional, non-randomized
Feb 2021 – Dec 2024, Denmark Full (2)
Emergency (56) Johnson & Johnson COVID-19 vaccine
Janssen Vaccines (Johnson & Johnson), BIDMC United States, Netherlands
Adenovirus vector (recombinant Ad26) 1 dose 2–8 °C Phase III (40,000)
Randomized, double-blinded, placebo-controlled
Positive results from an interim analysis were announced on 29 January 2021. J&J
reports an efficacy of 66% against mild and moderate symptoms, and 85% against
severe symptoms. Further, the mild and moderate efficacy ranged from 64% in
South Africa to 72% in the United States.
Jul 2020 – ? 2023, United States, Argentina, Brazil, Chile, Colombia, Mexico,
Peru, the Philippines, South Africa, Ukraine Full (1)
Emergency (55) CoronaVac
Sinovac China Inactivated SARS‑CoV‑2 (vero cells) 2 doses
2–3 weeks 2–8 °C Phase III (33,620)
Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.
Final Phase III results from Turkey showed an efficacy of 83.5%. A Chilean study
showed 65% efficacy against symptomatic cases, 87% against hospitalization, 90%
against ICU admissions, and 86% against deaths. Brazil announced results showing
50.7% effective at preventing symptomatic infections, 83.7% effective in
preventing mild cases, and 100% effective in preventing severe cases.
July 2020 – Oct 2021, Brazil (15,000); Aug 2020 – January 2021, Indonesia
(1,620); Chile (3,000); Turkey (13,000) Phase IV (37,867)
Interventional
Feb 2021 – Feb 2022, Serrana (São Paulo) (27,711); Mar 2021 – Mar 2022, Manaus
(10,156) Full (1)
Emergency (41) BBV152 (Covaxin)
Bharat Biotech, Indian Council of Medical Research India Inactivated SARS‑CoV‑2
(vero cells) 2 doses
4 weeks 2–8 °C Phase III (25,800)
Randomised, observer-blinded, placebo-controlled
Bharat Biotech self-reported an interim efficacy is 78% for its phase 3 trial.
Nov 2020 – Mar 2021, India. Full (0)
Emergency (16) Ad5-nCoV (Convidecia)
CanSino Biologics, Beijing Institute of Biotechnology of the Academy of Military
Medical Sciences China Adenovirus vector (recombinant Ad5) 1 dose 2–8 °C Phase
III (40,000)
Global multi-center, randomized, double-blind, placebo-controlled to evaluate
efficacy, safety and immunogenicity.
In February 2021, interim analysis from global trials showed an efficacy of
65.7% against moderate cases of COVID-19 and 90.98% efficacy against severe
cases.
Mar–Dec 2020, China; Sep 2020 – Dec 2021, Pakistan; Sep–Nov 2020, Russia, China,
Argentina, Chile; Mexico; Pakistan; Saudi Arabia Full (1)
Emergency (5) Sputnik Light
Gamaleya Research Institute of Epidemiology and Microbiology Russia Adenovirus
vector (recombinant Ad26) 1 dose 2–8 °C Phase III (7,000)
Randomised, double-blind, placebo-controlled trial
Feb  – Dec 2021, Russia (6,000) Full (0)
Emergency (5) WIBP-CorV
Sinopharm: Wuhan Institute of Biological Products China Inactivated SARS‑CoV‑2
(vero cells) 2 doses
3 weeks 2–8 °C Phase III (51,600)
Randomized, double-blind, placebo-controlled
Peer-reviewed results indicate 72.8% efficacy against symptomatic COVID-19.
Jul 2020 – Mar 2021, Bahrain, Egypt, Jordan, United Arab Emirates; Sep 2020 –
Sep 2021, Peru; Sep 2020 – Dec 2020, Morocco Full (1)
Emergency (1) EpiVacCorona
Vector Institute Russia Subunit (peptide) 2 doses
3 weeks 2–8 °C Phase III (40,150)
Randomized double-blind, placebo-controlled to evaluate efficacy,
immunogenicity, and safety
Nov 2020 – Dec 2021, Russia (3,000) Full (1)
Emergency (2) ZF2001 (RBD-Dimer)
Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. China Subunit (recombinant) 3
doses
30 days 2–8 °C Phase III (29,000)
Randomized, double-blind, placebo-controlled
Dec 2020 – Apr 2022, China, Ecuador, Indonesia, Malaysia, Pakistan, Uzbekistan
Full (0)
Emergency (2) CoviVac
The Chumakov Centre at the Russian Academy of Sciences Russia Inactivated
SARS‑CoV‑2 (vero cells) 2 doses
2 weeks 2–8 °C Phase III (32,000)
Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.
May 2021 – ?, Russia (3,000) Full (0)
Emergency (1) QazCovid-in (QazVac)
Research Institute for Biological Safety Problems Kazakhstan Inactivated
SARS‑CoV‑2 2 doses
3 weeks 2–8 °C Phase III (3,000)
Randomised, blind, placebo-controlled trial
Mar 2021 – Jul 2021, Kazakhstan Full (0)
Emergency (1) Minhai COVID-19 vaccine
Minhai Biotechnology Co., Shenzhen Kangtai Biological Products Co. Ltd. China
Inactivated SARS‑CoV‑2 (vero cell) 2 doses
4 weeks 2–8 °C Phase III (28,000)
Multi-national, Randomized, Double-blind, Placebo-controlled.
April–Nov 2021, China, the Philippines Full (0)
Emergency (1)


INTRESTING RESOURCES AND REFERENCES:

 * https://covid19-vaccine-tracker.com/
 * https://covid-nma.com/vaccines/mapping/
 * https://en.wikipedia.org/wiki/COVID-19_vaccine

https://covid-19-vaccine-tracker.com